# US 2026/0251540 A1 · Compositions and Methods for Whole Blood Preservation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0251540 A1
- Document ID: US20260251540A1
- Status: Published application
- Kind: A1
- Application number: 19/162,876
- Filed: 2024-03-06
- Published: 2026-08-27
- Earliest claimed: 2023-03-08
- Assignees: ImYoo Inc.
- Applicants: ImYoo Inc.
- Inventors: Jong Hwee Park; Tatyana Dobreva; David Brown
- Web page: https://patentgrep.com/patent/US20260251540A1

## CPC

- G01N 1/30: Staining; Impregnating {; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis}
- G01N 33/96: involving blood or serum control standard
- C12N 5/0634: {Cells from the blood or the immune system}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Systems and methods for small volume whole blood preservation are provided. Whole blood can be preserved Start and stored for an extended period of time at room temperature. The preserved whole blood can be used in single cell-based applications.

## Claims

### Claim 1

A solution for preserving whole blood, comprising:
a saccharide-epichlorohydrin copolymer; and
a molecular compound comprising an aldehyde functional group;
dissolved in a solution.

### Claim 2 (depends on 1)

The solution of claim 1, wherein the molecular compound comprising an aldehyde functional group is of: formaldehyde, paraformaldehyde, acetaldehyde, glutaraldehyde, or formalin.

### Claim 3 (depends on 1)

The solution of claim 1, wherein the molecular compound comprising an aldehyde functional group has a concentration ranging from 0.5% to 5.0% (% w/v).

### Claim 4 (depends on 1)

The solution of claim 1, wherein the saccharide-epichlorohydrin copolymer has a molecular weight from 60,000 Da to 500,000 Da.

### Claim 5 (depends on 1)

The solution of claim 1, wherein the saccharide-epichlorohydrin copolymer is sucrose-epichlorohydrin copolymer.

### Claim 6 (depends on 1)

The solution of claim 1, wherein the sucrose-epichlorohydrin copolymer is selected from the group consisting of: polysucrose, polysucrose 400, 2-(chloromethyl)oxirane; (2R,3R,4S,5S,6R)-2-[(2S,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy- 6-(hydroxymethyl)oxane-3,4,5-triol, Ficoll®, Ficoll® 70, and Ficoll® 400.

### Claim 7 (depends on 1)

The solution of claim 1, wherein the saccharide-epichlorohydrin copolymer has a concentration from 2% to 20% (% w/v).

### Claim 8 (depends on 1)

The solution of claim 1, wherein the solution is selected from the group consisting of: distilled water, deionized water, phosphate buffer, phosphate buffer solution, saline, HEPES buffer, MES buffer, MOPS buffer, PIPES buffer, potassium phosphate, sodium phosphate, TAPS, citric acid—sodium citrate buffer, bicarbonate buffer, and any combination thereof.

### Claim 9

A method to preserve whole blood, comprising:
contacting a whole blood sample with a solution for preserving whole blood, comprising, a saccharide-epichlorohydrin copolymer, and a molecular compound comprising an aldehyde functional group dissolved in a solution; and
adding a quencher to the whole blood solution.

### Claim 10 (depends on 9)

The method of claim 9, further comprising:
enriching nucleated cells from the whole blood solution; and
performing a single cell assay on the enriched nucleated cells.

### Claim 11 (depends on 9)

The method of claim 9, wherein a ratio (v/v) of the solution to the blood sample is equal to or greater than equal to about 10:1.

### Claim 12 (depends on 9)

The method of claim 9, wherein the whole blood sample has a volume from 20 μL to 1 mL.

### Claim 13 (depends on 9)

The method of claim 9, wherein the whole blood sample is collected using a capillary blood collection procedure.

### Claim 14 (depends on 9)

The method of claim 9, wherein the contacting step is performed at a temperature from 20° C. to 25° C.

### Claim 15 (depends on 9)

The method of claim 9, wherein the quencher comprises a molecular compound comprising an amine functional group, dissolved in a solution comprising a sucrose-epichlorohydrin copolymer.

### Claim 16 (depends on 15)

The method of claim 15, wherein the molecular compound comprising an amine functional group is provided as a tris buffer, a glycine buffer, or a combination thereof; wherein the tris buffer comprises a tris base selected from the group consisting of: tris(hydroxymethyl)aminomethane, Trizma® base, amino-2-(hydroxymethyl)-1,3-propanediol, 2-,2-Amino-2-(hydroxymethyl)-1,3-propanediol, THAM, tris(hydroxymethyl)aminomethane, and trometamol buffer.

### Claim 17 (depends on 15)

The method of claim 15, wherein the quencher has an equivalent or excess molar concentration to the molecular compound comprising the aldehyde functional group.

### Claim 18 (depends on 15)

The method of claim 15, wherein the solution further comprises ethylenediaminetetraacetic acid.

### Claim 19 (depends on 9)

The method of claims 9, wherein the quencher is provided in a quenching solution in a ratio (v/v) to the solution equal to or greater than 2.

### Claim 20 (depends on 9)

The method of claims 9, wherein the adding the quencher step is performed 45 minutes to 80 minutes after the contacting step.

### Claim 21 (depends on 9)

The method of claims 9, wherein the quencher comprises a molecular compound comprising an amine functional group, dissolved in a solution comprising sucrose-epichlorohydrin copolymer.

### Claim 22 (depends on 9)

The method of claims 9, wherein the quencher is provided in a quenching solution in a ratio (v/v) to the solution equal to or greater than 2.

### Claim 23 (depends on 9)

The method of claims 9, further comprising storing the quenched whole blood solution at a temperature from 20° C. to 25° C. for at least 24 hours or at least 72 hours.

### Claim 24 (depends on 10)

The method of claim 10, wherein the nucleated cells comprise PBMCs.

### Claim 25 (depends on 24)

The method of claim 24, further comprising isolating PBMCs from the quenched whole blood solution using a method selected from the group consisting of: centrifugation, density gradient centrifugation, a cell preparation tube, a PBMC isolation tubes, a magnetic cell separation kit, immunoprecipitation, immune separation, and column purification.

### Claim 26 (depends on 24)

The method of claim 24, further comprising storing the isolated PBMCs in a freezer or using a cryogenic liquid.

### Claim 27 (depends on 10)

The method of claim 10, wherein a single cell assay comprises single cell RNA sequencing (scRNA-seg).

### Claim at position 28

28-50. (canceled)
